Sixty-four eyes were prospectively investigated. Group 1 (22 central retinal vein occlusion (CRVO) and 16 branch retinal vein occlusion (BRVO)) was treated with Ozurdex alone, and group 2 (14 CRVO and ...

To evaluate the morphological and functional changes following intravitreal Ozurdex (dexamethasone implant) injections in patients with macular oedema (MO) secondary to retinal vascular diseases. The ...

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE: AGN) announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a ...

A sustained-release dexamethasone device implanted during pars plana vitrectomy may be effective in pre-emptively reducing macular edema in patients with various underlying ocular diseases at risk for ...

Purpose To report outcome of eyes with recalcitrant and naive eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone implants (Ozurdex) injection. Methods Retrospective ...

OZURDEX (dexamethasone) intravitreal implant by Allergan The FDA has approved Ozurdex (dexamethasone intravitreal implant, from Allergan) for the treatment of non-infectious ocular inflammation, or ...

Biodegradable implant delivers extended-release corticosteroid dexamethasone via intravitreal injection. FDA cleared Allergan’s Ozurdex® 0.7 mg for noninfectious ocular inflammation, or uveitis, ...

OZURDEX (dexamethasone) intravitreal implant by Allergan Allergan's Ozurdex (dexamethasone intravitreal implant) has been approved by the FDA for the treatment of macular edema following branch ...

California-based pharmaceutical company Allergan Inc. has won the approval of federal health regulators for a new use of its biodegradable eye implant Ozurdex. On Monday, the U.S. Food and Drug ...